Clinical Trial to Evaluate the Efficacy and Safety of Platelet-rich Plasma Infiltration in Chronic Omalgia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Platelet-rich Plasma Local injection, betamethasone and Ropivacaine.
- Who it may be relevant to
- Registry conditions: Chronic Pain. Basic parameters: 35 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Spain
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Randomized Clinical Trial to Evaluate the Efficacy and Safety of Platelet-Rich Plasma (PRP) Injection Combined With Physical Exercise in Chronic Omalgia
Overview
The experimental group will receive intralesional injections of platelet-rich plasma, evaluating its ability to relieve pain and provide sustained improvement through biological modulation of the joint and tendon environment. In contrast, the control group will be treated with a combination of betamethasone and ropivacaine, representing the current standard of care for short-term inflammatory pain management. The comparison between these two options will determine whether platelet-rich plasma offers advantages in terms of clinical efficacy and duration of benefits. The results obtained could contribute significantly to the development of more effective protocols and more precise management guidelines for patients with chronic omalgia, thus addressing existing controversies and improving clinical practice.
Interventions
- Biological Platelet-rich Plasma Local injection
Two procedures are considered for obtaining an equivalent PRP formulation, with the aim of establishing a contingency plan for possible situations such as a shortage of specific materials (extraction tubes) or the unavailability of a dedicated clean room for preparation under open circuit conditions. PRP produced in-house, following the open technique, is prepared in a laminar flow cabinet within an environment that complies with the standards of asepsis and Good Manufacturing Practices required - Drug betamethasone and Ropivacaine
consists of a mixture of 2 cc of betamethasone and 2 cc of ropivacaine. To prepare it, 2 cc of betamethasone will be extracted from an ampoule of injectable solution using a sterile syringe (without attaching the needle) and mixed with 2 cc of ropivacaine.
Primary outcome measures
- functional improvement between the intervention group and the control group measured by the absolute change in the Constant-Murley scale score [Time frame: 36 months]
Eligibility criteria
Inclusion criteria
- Patients between 35 and 75 years of age, both inclusive.
- Presence of pain in the affected shoulder for 3 or more months.
- Body Mass Index (BMI) values between 20 and 27 kg/m2, including both values.
- Confirmed diagnosis of chronic shoulder pain associated with rotator cuff tendinopathy, following an unfavorable response to standard treatment with analgesics and nonsteroidal anti-inflammatory drugs for 4-6 weeks.
- Patients who agree to participate in the study and sign the informed consent form.
Exclusion criteria
- Confirmed diagnosis of complete rotator cuff tear.
- Patients with systemic autoimmune rheumatic disease (connective tissue diseases and systemic necrotizing vasculitis).
- Patients with diabetes mellitus.
- Patients with hematological disorders (thrombopathy, thrombocytopenia, anemia with Hb<9 g/dl).
- Patients undergoing immunosuppressive treatment at the time of inclusion.
- Patients undergoing treatment with intramuscular corticosteroids in the 3 months prior to the first administration of the trial treatment.
- Patients undergoing treatment with nonsteroidal anti-inflammatory drugs (more than 10 consecutive days at usual doses), opioids, or oral corticosteroids during the 15 days prior to treatment in the study.
- Patients with severe heart disease.
- Patients with active cancer or cancer diagnosed in the last 5 years.
- Patients who are taking a drug in clinical trials or have participated in any clinical trial (with an authorized or unauthorized product) in the 30 days prior to randomization.
- Patients with any physical, social, or psychological condition that, in the opinion of the investigators, may affect the patient's participation in the trial or the validity of the data obtained from their participation in it.
- Pregnant women.
- Breastfeeding women.
- Women of childbearing age\* who are unable or unwilling to use contraceptive methods with a failure rate of <1% per year (bilateral tubal ligation, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices) during the four-week treatment period.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Spain · 2 centers
- Hospital Universitario Cruces — Barakaldo
- Hospital Universitario Basurto — Bilbao
Identifiers
NCT: NCT07448285 · SHIELD-PRP